To review the pharmacology, pharmacokinetics, clinical efficacy, and adverse effects of montelukast, a leukotriene receptor antagonist used to treat asthma, and to discuss the therapeutic role of montelukast as long-term medication and difficulties associated with the management of asthma.
DATA SOURCES:
A MEDLINE search (up to May 1999) was conducted to identify relevant English-language publications, including preclinical studies, clinical trials, and recent reviews.
STUDY SELECTION:
All available published reports of controlled, clinical trials of montelukast in adults and children with asthma were summarized, including pharmacokinetic and pharmacologic effects of montelukast.
DATA EXTRACTION:
Information on the safety and efficacy of montelukast was evaluated on the basis of patient selection, study design, methodology, and statistical significance as compared with placebo or inhaled corticosteroid treatment.
DATA SYNTHESIS:
Montelukast is approved for the prophylaxis and chronic treatment of asthma at a dose of 10 mg once daily for adolescents (=15 y) and adults and 5 mg once daily for children (6–14 y). In placebo-controlled clinical trials, montelukast significantly improved pulmonary lung function (as measured by forced expiratory volume in 1 sec), significantly reduced β2-agonist use, and significantly improved patient-reported end points in adults and children (=6 y) with chronic asthma. In adults, a similar magnitude of improvement in lung function is seen with or without inhaled corticosteroid use; the effects of montelukast may be additive to those of inhaled corticosteroids and permit the reduction of the required dose of inhaled corticosteroids. In cases of exercise-induced asthma (adults and children), montelukast treatment attenuates the fall in pulmonary function following exercise. It attenuates both the early- and late-phase responses of asthma after allergen inhalation. Improvements in asthma control are similar in asthmatic patients who are aspirin-sensitive or not aspirin-sensitive and can be seen within one day of treatment. Tolerance does not develop, and the adverse events do not differ from those of placebo.
CONCLUSIONS:
Montelukast is indicated for the prophylaxis of chronic asthma in adults and children (=6 y). It may be considered for use as first-line therapy in patients with mild persistent asthma or for additional control in patients who are still symptomatic while receiving treatment with inhaled corticosteroids. It may also be used for additional control in aspirin-sensitive asthmatic patients. Consideration may be given for using montelukast to allow tapering of the dose of inhaled corticosteroids while maintaining clinical stability. Chronic treatment with montelukast can provide additional control of symptoms during exercise, but inhaled β2-agonists remain first-line therapy for prophylaxis and treatment.
AdamsPFMaranoMA. Current estimates from the National Health Interview Survey, 1994. Vital Health Stat1995;10: 94.
2.
Surveillance for asthma — United States, 1960–1995. MMWR Morb Mortal Wkly Rep1998;47: 1–26.
3.
Centers for Disease Control and Prevention. Asthma mortality and hospitalization among children and young adults — United States, 1990–1993. MMWR Morb Mortal Wkly Rep1996;45:350–3.
4.
JefferyPKGodfreyRWAdelrothENelsonFRogersAJohanssonSA. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma: Quantitative light and electron microscopic study. Am Rev Respir Dis1992;145 (4, pt 1): 890–9.
5.
JefferyPKWardlawAJNelsonFCCollinsJVKayAB. Bronchial biopsies in asthma: An ultrastructural, quantitative study and correlation with hyperactivity. Am Rev Respir Dis1989;140: 1745–53.
6.
WenzelSESzeflerSJLeungDYSloanSIRexMDMartinRJ. Bronchoscopic evaluation of severe asthma: Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med1997;156 (3, pt 1): 737–43.
7.
National Heart, Lung, Blood Institute, National Asthma Education Program, Expert Panel Report II. Guidelines for the diagnosis and management of asthma. Pub. no. 97–4051. Bethesda, MD: US Department of Health and Human Services, 1997.
8.
HaahtelaTJarvinenMKavaTKivirantaKKoskinenSLehtonenKEffects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med1994;331:700–5.
9.
KellowayJSWyattRAAdlisSA. Comparison of patients' compliance with prescribed oral and inhaled asthma medications. Arch Intern Med1994;154: 1349–52.
10.
BootAMde JongsteJCVerberneAAPHPoisHAPde Muinck Keiz-Er-SchramaSMPF. Bone mineral density and bone metabolism of prepubertal children with asthma after long-term treatment with inhaled corticosteroid. Pediatr Pulmonol1997;24: 379–84.
11.
SimonsFE. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone Dipropionate — Salmeterol Xinofoate Study Group. N Engl J Med1997;337: 1659–65.
12.
CrowleySTrivediPRisteliLRisteliJHindmarshPCBrookCG. Collagen metabolism and growth in prepubertal children with asthma treated with inhaled steroids. J Pediatr1998;132: 409–13.
13.
ColemanRAEglenRMJonesRLNarumiyaSShimizuTSmithWLProstanoid and leukotriene receptors: A progress report from the IUPHAR working parties on classification and nomenclature. Adv Prostaglandin Thromboxane Leukot Res1995;23:283–5.
14.
HendersonER. The role of leukotrienes in inflammation. Ann Intern Med1994;121: 684–97.
15.
DrazenJMAustenKF. Leukotrienes and airway responses. Am Rev Respir Dis1987;136: 985–98.
16.
DrazenJMIsraelEO'ByrnePM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med1999;340: 197–206.
17.
HarrisRRCarterGWBellRLMooreJLBrooksDW. Clinical activity of leukotriene inhibitors. Int J Immunopharmacol1995;17: 147–56.
18.
HolgateSTBraddingBMSampsonAP. Leukotriene antagonists and synthesis inhibitors: New directions in asthma therapy. J Allergy Clin Immunol1996;98: 1–13.
19.
BarnesNCLuitertLM. Drugs affecting the leukotriene pathway in asthma. Br J Clin Pract1995;49: 262–6.
20.
DahlenSKumlinMBjorckTRaudJHedqvistP. Airway smooth muscle and disease workshop: Leukotrienes and related eicosanoids. Am Rev Respir Dis1987;136 (4 pt 2): S24–8.
21.
MaltbyNHTaylorGWRitterJMooreKFullerRWDolleryCT. Leukotriene C4 elimination and metabolism in man. J Allergy Clin Immunol1990;85: 3–9.
22.
GrossNJ. Leukotriene modifiers: What place in asthma management? J Respir Dis1998;19: 245–61.
23.
IsraelERubinPKempJPGrossmanJPiersonWSiegelSCThe effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med1993;119:1059–66.
24.
O'ByrnePMIsraelEDrazenJM. Antileukotrienes in the treatment of asthma. Ann Intern Med1997;127: 472–80.
25.
SpectorSLSmithLJGlassM. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATEM Asthma Trialists Group. Am J Respir Crit Care Med1994;150: 618–23.
26.
De LepeleireIReissTFRochetteFBottoAZhangJKundoSMontelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma. Clin Pharmacol Ther1997;61:83–92.
27.
JonesTRLabelleMBelleyMChampionECharetteLEvansJPharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol1995;73:191–201.
28.
LynchKRO'NeillGPLiuQImD-SSawyerNMettersKMCharacterization of the human cysteinyl leukotriene CysLT1 receptor. Nature1999;399:789–93.
29.
SarauHMAmesRSChambersJEllisCElshourbagyNFoleyJJIdentification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Molecular Pharmacology1999;56:657–63.
30.
ChengHLeffJAAminRGertzBJDe SmitMNoonanNPharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm Res1996;13:445–8.
31.
SchoorsDFDe SmetMReissTMargolskeeDChengHLarsonPSingle dose pharmacokinetics, safety and tolerability of MK-0476, a new leukotriene D4-receptor antagonist, in healthy volunteers. Br J Clin Pharmacol1995;40:277–80.
32.
ZhaoJJRogersJDHollandSDLarsonPAminRDHaesenRPharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. Biopharm Drug Dispos1997;18:769–77.
33.
BalaniSKXuXPrathaVKossMAAminRDDufresneCMetabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile. Drug Metab Dispos1997;25:1282–7.
34.
AltmanLCMunkZSeltzerJNoonanNShingeSZhangJA placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. J Allergy Clin Immunol1998;102:50–6.
35.
NoonanMJChervinskyPBrandonMZhangJKunduSMcBurneyJMontelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Eur Respir J1998;11:1232–9.
36.
BronskyEAKempJPZhangJGuerreiroDReissTF. Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval. Clin Pharmacol Ther1997;62: 556–61.
37.
KempJPDockhornRJShapiroGGNguyenHHReissTFSeidenbergBCMontelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr1998;133:424–8.
38.
LeffJABusseWWPearlmanDBronskyEAKempJHendelesLMontelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med1998;339:147–52.
39.
ReissTFWhiteRNoonanGKorenblatPHessFShingoS. Montelukast (MK-0476), a CysLT1 receptor antagonist, improves the signs and symptoms of asthma over one year of treatment (abstract). Eur Respir J1997;10 (suppl 25):437s.
40.
KnorrBNguyenHVillaranCKearnsGBozaMRogersJSelection of a montelukast dose in 2- to 5-year-olds by a comparison of pediatric and adult single-dose population pharmacokinetic (PK) profiles (abstract). Clin Pharmacol Ther1998;63:191A.
41.
KnorrBMatzJBernsteinJANguyenHSeidenbergBCReissTFMontelukast for chronic asthma in 6- to 14-year-old children: A randomized, double-blind trial. JAMA1998;279:1181–6.
42.
ReissTFChervinskyPDockhornRJShingoSSeidenbergBEdwardsTB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma. Arch Intern Med1998;158: 1213–20.
43.
ReissTFChervinskyPNoonanMPrennerBZhangJHessJMK-0476, an LTD-4 receptor antagonist, exhibits a dose related improvement in the once daily treatment of patients with chronic asthma (abstract). Eur Respir J Suppl1995;19:289s.
44.
MalmstromKRodriguez-GomezGGuerraJVillaranCPiñeiroAWeiLOral montelukast, inhaled beclomethasone, and placebo for chronic asthma. Ann Intern Med1999;130:487–95.
45.
VillaranCO'NeillSJHelblingAvan NoordJALeeTHChuchalinAGMontelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. J Allergy Clin Immunol1999;104:547–53.
46.
ReissTFSorknessCAStrickerWBottoABusseWWKunduSEffects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax1997;52:45–8.
47.
ReissTFAltmanLCChervinskyPBewtraAStrickerWENoonanGPEffects of montelukast (MK-0476), a new cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol1996;98:528–34.
48.
GibsonPGWlodarczykJWHensleyMJGleesonMHenryRLCrippsAWEpidemiological association of airway inflammation with asthma symptoms and airway hyperresponsiveness in childhood. Am J Respir Crit Care Med1998;158:36–41.
49.
PizzichiniELeffJAReissTFHendelesLBouletLPWeiLXMontelukast reduces airway eosinophilic inflammation in asthma: A randomized, controlled trial. Eur Respir J1999;14:12–8.
50.
Package insert. Flovent (fluticasone). Research Triangle Park, NC: Glaxo Wellcome, 1999.
51.
TurpinJAEdelmanJMDeLuccaPTPearlmanDS. Chronic administration of montelukast (MK-0476) is superior to inhaled salmeterol in the prevention of exercise-induced bronchoconstriction (EIB) (abstract). Am J Respir Crit Care Med1998;157: A456.
52.
DiamantZGrootendorstDCVeselic-CharvatMTimmersMCDe SmetMLeffJAThe effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma. Clin Exp Allergy1999;29:42–51.
53.
KunaPMalmstromKDahlenSENizankowskaEKowalskiMStevensonDMontelukast (MK-0476), a CysLT1 receptor antagonist, improves asthma control in aspirin-intolerant asthmatic patients (abstract). Am J Respir Crit Care Med1997;155:A975.
54.
O'ConnorBJGodardPDubeLMSwansonLJRountreeLV. the European Zileuton Study Group. The effect of a 5-lipoxygenase inhibitor, zileuton, plus a low-dose inhaled beclomethasone alone in patients with asthma (abstract). Am J Respir Crit Care Med1996;153: A803.
55.
NayakASAndersonPJCharousBLWilliamsKLMillerCJBonuccelliCMAddition of zafirlukast compared with a doubled dosage of inhaled corticosteroids in asthmatic patients with symptoms on inhaled corticosteroids (abstract). Eur Respir J Suppl1998;12 (suppl 28): 361S.
56.
LeffJAIsraelENoonanMJFinnAFGodardPLofdahlCGMontelukast (MK-0476) allows tapering of inhaled corticosteroids (ICS) in asthmatic patients while maintaining clinical stability (abstract). Am J Respir Crit Care Med1997;155:A976.
57.
CrockerICZhouCYBewtraAKKreutnerWTownleyRG. Glucocorticosteroids inhibit leukotriene production. Ann Allergy Asthma Immunol1997;78: 497–505.
58.
DworskiRFitzgeraldGAOatesJAShellerJR. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med1994;149: 953–9.
59.
NoonanGReissTFShingoSNguyenHHKnorrB. Montelukast (MK-0476) maintains long-term asthma control in adult and pediatric patients (aged ≥6 years). Am J Respir Crit Care Med1999;159: A640.
60.
MalmstromKMeltzerEPrennerBLuSWeinsteinSWolfeJEffects of montelukast (a leukotriene receptor antagonist), loratadine, montelukast + loratadine and placebo in seasonal allergic rhinitis and conjunctivitis (abstract). J Allergy Clin Immunol1998;101 (suppl):S97.
61.
GustafssonLE. Exhaled nitric oxide as a marker in asthma. Eur Respir J1998;26 (suppl):49S–52S.
62.
BarnesPJKharitonovSA. Exhaled nitric oxide: A new lung function test. Thorax1996;51: 233–7.
63.
BisgaardHLolandLOjJA. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med1999;160: 1227–31.
64.
WechslerMEGarpestadEFlierSRKocherOWeilandDAPolitoAJPulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA1998;279:455–7.
65.
GreenRLVayonisAG. Churg–Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatment. Lancet1999;353: 725–6.
66.
ChurgABrallasMCroninSRChurgJ. Formes frustes of Churg– Strauss syndrome. Chest1995;108: 320–3.
67.
ChibaMXuXNishimeJABalaniSKLinJH. Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans. Drug Metab Dispos1997;25: 1022–31.
68.
HollandSShahaneARogersJDPorrasAGrasingKLasseterKMetabolism of montelukast (M) is increased by multiple doses of phenobarbital (abstract). Clin Pharmacol Ther1998;63:231A.
69.
SchwartzJLarsonPEbelDHuntTGertzB. Lack of impact of a leukotriene (LT) D4 receptor antagonist, montelukast (M), on ethinyl estradiol (EE) and norethindrone (NET) serum concentrations (abstract). Clin Pharmacol Ther1997;61: 162.
70.
HollandSGertzBDesmetMMichielsNLarsonPFreemanAMontelukast has no effect on terfenadine pharmacokinetics or QTc (abstract). Clin Pharmacol Ther1998;63:232A.
71.
MalmstromKSchwartzJReissTFSullivanTJReeseJHJaureguiLEffect of montelukast on single-dose theophylline pharmacokinetics. Am J Ther1998;5:189–95.
72.
Van HeckenADepréMVerbesseltRWynantsKDe LepeleireIArnoutJEffect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol1999;39:495–500.
73.
AwniWMCavanaughJHBraeckmanRAChuSYPattersonKJMachinistJMThe effect of mild or moderate hepatic impairment (cirrhosis) on the pharmacokinetics of zileuton. Clin Pharmacokinet1995;29 (suppl 2):49–61.
74.
AgertoftLPedersenS. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med1994;88: 373–81.
75.
AllenDBBronskyEALaForceCFNathanRATinklemanDGVandewalkerMLGrowth in asthmatic children treated with fluticasone propionate. J Pediatr1998;132:472–7.
76.
AgertoftLPedersenS. Bone mineral density in children with asthma receiving long-term treatment with inhaled budesonide. Am J Respir Crit Care Med1998;157: 178–83.
77.
FDA requires new pediatric labeling for inhaled, intranasal corticosteroids. FDA Talk Paper. Bethesda, MD: Food and Drug Administration, November 9, 1998.
78.
GarbeELeLorierJBolvinJ-FSuissaS. Inhaled and nasal glucocorticosteroids and the risks of ocular hypertension or open-angle glaucoma. JAMA1997;277: 722–7.
79.
CummingRGMtchellPLeederSR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med1997;337: 8–14.
80.
GarbeE. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA1998;280: 539–43.
81.
ClarkDJGroveACargillRILipworthBJ. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax1996;51: 262–6.
82.
LedfordDApterABrennerA ManonRubinKPrestwoodKFrieriMOsteoporosis in the corticosteroid-treated patient with asthma. J Allergy Clin Immunol1998;102:353–62.
83.
VerberneAAPHFullerR. An overview of nine clinical trials of salmeterol in an asthmatic population. Respir Med1998;92: 777–82.
84.
NielsonCPHadjokasNE. Beta-adrenoceptor agonists block corticosteroid inhibition in eosinophils. Am J Respir Crit Care Med1998;157: 184–91.
85.
RamageLLipworthBJIngramCGCreeIADhillonDP. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med1994;88: 363–8.
86.
InmanMDO'ByrnePM. The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. Am J Respir Crit Care Med1996;153: 65–9.
87.
NelsonJAStraussLSkowronskiMCiufoRNovakRMcFaddenERJr. Effect of long-term salmeterol treatment on exercise-induced asthma. N Engl J Med1998;339: 141–6.
88.
Hansen-FlaschenJSchotlandH. New treatments for exercise-induced asthma (editorial). N Engl J Med1998;339: 192.
89.
GianniniDCarlettiADenteFLBacciEDiFrancoAVagagginiBTolerance to the protective effect of salmeterol on allergen challenge. Chest1996;110:1452–7.
90.
DrotarDEDavisEECockcroftDW. Tolerance to the bronchoprotective effect of salmeterol 12 hours after starting twice daily treatment. Ann Allergy Asthma Immunol1998;80: 31–4.
91.
CramerJVachonLDesforgesCSussmanNM. Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial. Epilepsia1995;36: 1111–7.
92.
CasaleTB. Compliance and oral therapy for asthma. Allergy Clin Immunol Int1997;9: 72–8.
93.
CouttsJAPGibsonNAPatonJY. Measuring compliance with inhaled medication in asthma. Arch Dis Child1992;67: 332–3.
94.
BosleyCMFosburyJACochraneGM. The psychological factors associated with poor compliance with treatment in asthma. Eur Respir J1995;8: 899–904.
95.
MilgromHBenderBAckersonLBowryPSmithBRandC. Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol1996;98 (6, pt 1): 1051–7.
96.
RingdalNWhitneyJGSummertonL. Problems with inhaler technique and patient preference for oral therapy — Tablet zafirlukast vs. inhaled beclomethasone (abstract). Am J Respir Crit Care Med1998;157: A416.
97.
VirchowJCHassalSMSummertonLHarrisA. Improved asthma control over 6 weeks with Accolate (zafirlukast) in patients on high-dose inhaled corticosteroids (abstract). J Investig Med1997;45:286A.
